Search Results - Konstanze Döhner

Refine Results
  1. 1
    Molecular characterization of acute myeloid leukemia

    Molecular characterization of acute myeloid leukemia by Konstanze Döhner, H. Döhner

    Published 2008
    Get full text Get full text
    Editorial
    Save to List
    Saved in:
  2. 2
    Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?

    Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? by Peter Paschka, Konstanze Döhner

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    TET Genes: new players in DNA demethylation and important determinants for stemness

    TET Genes: new players in DNA demethylation and important determinants for stemness by Fabian Mohr, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B

    Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B by Stefan Fröhling, Richard F. Schlenk, Sabine Käyser, Martina Morhardt, Axel Benner, Konstanze Döhner, Hartmut Döhner

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

    Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut) by Jochen Greiner, Vanessa Schneider, Michael Schmitt, Marlies Götz, Konstanze Döhner, Markus Wiesneth, Hartmut Döhner, Susanne Hofmann

    Published 2013
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  6. 6
    Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

    Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms by Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Hartmut Döhner, Konstanze Döhner, Marcus M. Schittenhelm

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

    Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm by Stefan Fröhling, Richard F. Schlenk, Jochen Breitruck, Axel Benner, Sylvia Kreitmeier, Karen Tobis, Hartmut Döhner, Konstanze Döhner

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia

    Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia by Lars Bullinger, Konstanze Döhner, Eric Bair, Stefan Fröhling, Richard F. Schlenk, Robert Tibshirani, Hartmut Döhner, Jonathan R. Pollack

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

    Quantitative DNA methylation predicts survival in adult acute myeloid leukemia by Lars Bullinger, Mathias Ehrich, Konstanze Döhner, Richard F. Schlenk, Hartmut Döhner, Matthew R. Nelson, Dirk van den Boom

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia

    Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia by Brenton G. Mar, Lars Bullinger, Ellen M. Basu, Krysta Schlis, Lewis B. Silverman, Konstanze Döhner, Scott A. Armstrong

    Published 2012
    Get full text
    Carta
    Save to List
    Saved in:
  11. 11
    SEURAT: Visual analytics for the integrated analysis of microarray data

    SEURAT: Visual analytics for the integrated analysis of microarray data by Alexander Gribov, Martin Sill, Sonja C Lück, Frank G. Rücker, Konstanze Döhner, Lars Bullinger, Axel Benner, Antony Unwin

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia by Hartmut Döhner, Stephan Stilgenbauer, Axel Benner, Elke Leupolt, Alexander Kröber, Lars Bullinger, Konstanze Döhner, Martin Bentz, Peter Lichter

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    <i>CEBPA</i> Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations

    <i>CEBPA</i> Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations by Stefan Fröhling, Richard F. Schlenk, Ina Stolze, Jörg Bihlmayr, Axel Benner, Sylvia Kreitmeier, Karen Tobis, Hartmut Döhner, Konstanze Döhner

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Functional Classification of TP53 Mutations in Acute Myeloid Leukemia

    Functional Classification of TP53 Mutations in Acute Myeloid Leukemia by Sayantanee Dutta, Gudrun Pregartner, Frank G. Rücker, Ellen Heitzer, Armin Zebisch, Lars Bullinger, Andrea Berghold, Konstanze Döhner, Heinz Sill

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients &gt;60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

    DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (V... by Olga Grishina, Claudia Schmoor, Konstanze Döhner, Björn Hackanson, Beate Lubrich, Annette M. May, Caroline Cieslik, Michael J. Müller, Michael Lübbert

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

    Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations by Konstanze Döhner, Richard F. Schlenk, Marianne Habdank, Claudia Scholl, Frank G. Rücker, Andrea Corbacioglu, Lars Bullinger, Stefan Fröhling, Hartmut Döhner

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of <i>Mycobacterium tuberculosis</i> in Human Macrophages

    Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of <i>Mycobacterium tuberculosis</i> in Human Macrophages by Heiko Bruns, Frank Stegelmann, Mario Fabri, Konstanze Döhner, Ger van Zandbergen, Manfred Wagner, Mhairi Skinner, Robert L. Modlin, Steffen Stenger

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?

    ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance? by Stephany Corrêa, Eliana Abdelhay, Peter Paschka, Verena I. Gaidzik, Rocı́o Hassan, Rainer Claus, Richard F. Schlenk, Konstanze Döhner, Lars Bullinger

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    getITD for FLT3-ITD-based MRD monitoring in AML

    getITD for FLT3-ITD-based MRD monitoring in AML by Tamara J. Blätte, Laura K. Schmalbrock, Sabrina Skambraks, Susanne Lux, Sibylle Cocciardi, Anna Dolnik, Hartmut Döhner, Konstanze Döhner, Lars Bullinger

    Published 2019
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  20. 20
    Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by<i>DNMT3A</i>mutational status and associated with predominant hypomethylation of HOX genes

    Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by<i>DNMT3A</i>mutational status and associated with predominant hypomethylation of HOX ge... by Ying Qu, Andreas Lennartsson, Verena I. Gaidzik, Stefan Deneberg, Mohsen Karimi, Sofia Bengtzén, Martin Höglund, Lars Bullinger, Konstanze Döhner, Sören Lehmann

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: